Sana Biotechnology, Inc. SANA 深 沪
已收盘 02-06 16:00:00 美东时间
3.93
+0.380
+10.70%
华盛通- 最 高3.995
- 今 开3.69
- 成交量 327.35万股
- 最 低 3.685
- 昨 收 3.55
- 总市值 10.47亿
- 52周最高 6.55
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.26
- 委 比 -43.56%
- 总股本 2.66亿
- 历史最高 44.60
- 量 比 1.36
- 振 幅 8.73%
- 历史最低 1.26
- 每 手 1
- 风险率 1.12%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Sana Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference
Sana Biotechnology will present at the 44th J.P. Morgan Healthcare Conference on January 14, 2026, at 9:45 a.m. PT. The presentation, featuring Steve Harr, CEO, will provide a business overview and updates. The webcast and replay will be available on Sana's Investor Relations page for 30 days post-conference.
01-07 21:26
美股大行评级 | 拼多多、小鹏获Freedom上调目标价；多家大行首予Wealthfront"超配"评级，目标价最高23美元
今日重点评级关注：HC Wainwright & Co.：维持MetaVia Inc."买入"评级，目标价从12美元升至40美元；Canaccord Genuity：维持GH Research"买入"评级，目标价从35美元升至39美元
01-07 17:25
B of A Securities Maintains Buy on Sana Biotechnology, Raises Price Target to $7
B of A Securities maintains Sana Biotechnology (NASDAQ:SANA) with a Buy and raises the price target from $6 to $7.
01-07 01:15
美股周涨跌榜 | 特朗普媒体科技集团周涨51.1%，拟并购TAE转型聚变能源公司；Medline周涨43.6%
DJT周涨51.1%，拟并购TAE转型聚变能源公司；Medline周涨43.6%，本周首挂上市，为年内全球最大规模IPO；爱美医疗周涨34.4%，获拜玛林制药48亿美元收购>>
2025-12-20 09:40
Sana Biotechnology Says Nature Biotechnology Publishes Journal Article Titled "In Vivo Gene Editing Of Human Hematopoietic Stem And Progenitor Cells Using Envelope-Engineered Virus-Like Particles"
Data Demonstrate Potent in vivo Gene Editing of Hematopoietic Stem Cells (HSCs) in the Bone Marrow with Systemic Delivery in Preclinical Murine Models Using Fusogen Technology Broadens Application of Fusogen
2025-12-08 22:05
美股牛股 | Arrowhead制药飙升23%，行业首个微粒血症商用药物获FDA批准；DeFi大涨20%
Arrowhead制药飙升23%，行业首个微粒血症商用药物获FDA批准，最新财报强劲超预期；DeFi大涨20%，公司宣布QCAD数字信托获批为加拿大首个合规的加元稳定币>>
2025-11-27 16:04
Sana Biotechnology to Present at December 2025 Investor Conferences
Sana Biotechnology, Inc. will webcast presentations at Citi’s 2025 Global Healthcare Conference on December 2 and the 8th Annual Evercore Healthcare Conference on December 3. CEO Steve Harr will provide business updates. The webcasts and replays are available on Sana’s Investor Relations page.
2025-11-24 21:05
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 17:17
Sana暂停开发同种异体CAR-T
当下，CAR细胞疗法的下一代开发策略主要分为两个路线，一个是发展已久的异体来源的“现货型”、一个是异军突起的in vivo（体内）。但就目前的形势来看，无论是投...
2025-11-10 12:31
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 10:22
